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when given as 600mg twice daily. The optimal dosage of line-
zolid requires further delineation through balancing efﬁcacy
and toxicity.
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Background: Research studies reveal that green tea con-
ains catechins, polyphenols and related compounds possess
ariety anti-tumor effects and bactericidal properties. This
tudy is meant to evaluate the antimicrobial potential of
queous crude extract of dried leaves of Camellia sinensis
Green Tea) against H.pylori in vivo and in vitro conditions.
Methods: A total of 250 biopsies were collected from
he patients of gastro-duodenal pathology from govern-
ent sector hospitals in Karachi, Pakistan. All these biopsies
ere processed for detection of H.pylori by rapid Heli-
ourease, culture and polymerase chain reaction (PCR) for
he 16S ribosomal gene of H.pylori. All the isolates were
creened for their susceptibility against antibiotics and
queous extract of Camellia sinensis (Green Tea) by agar
ell diffusion as well as micro-broth dilution. In-vivo stud-
es were carried out by developing Gastritis Models (divided
nto 4 groups and each has got 3 test mice and 1 control
ouse) in BALB/c mice by infecting orally with sub-lethal
oses of 100 !l of 10 7ml of H pylori culture. The gastritis
odel was developed after inoculation H.pylori for about
days, 14 days, 21 days, 28 days and 34 days with subse-
uent doses of 5% aqueous extract of geen tea whose MIC
as 28mg/ml.
Results: In this study, a total of 88, clinical H pylori iso-
ates were isolated and identiﬁed by rapid and molecular
ethods and our isolates showed a high level resistance
owards Tetracyclin (60%), Metronidazole (80%), and Amox-
cillin (60%), Erythromycin (40%), Clarithromycin (30%),
ﬂoxicin (8%).A signiﬁcantly large zone of an average 21mm
as found on most of the isolates in case of in-vitro studies.
oreover, 4 fold reductions of Cfu/ g was noted in 7 days, 14
ays and 21 days, but fairly moderate CFU/g was observed
n control upon organ culture. The results were also found in
greement to the histopathological ﬁndings of the stomach
ndicating successful establishment of infection and gastritis
nd upon treatment by the green tea, the reduction in the
io-load
Conclusion: Owing to the exorbitantly high resistance like
n Metronidazole that is a cause of the failure of treatment
n combined therapy, the results of the current study provide
seful insights to the developments of new antimicrobial
gent like green tea as a therapeutic intervention tool.
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arious dosages of linezolid in treatment of difﬁcult
ultidrug-resistant tuberculosis
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Background: Linezolid has a potential role in treatment of
omplicated multidrug-resistant tuberculosis (MDR-TB) and
xtensively drug-resistant tuberculosis (XDR-TB). However,
ore clinical experience is desirable regarding its dosing and
olerance.
Methods: All patients treated with linezolid plus other
econd-line drugs in a tertiary tuberculosis center for
uoroquinolone-resistant MDR-TB or XDR-TB from May 2004
o January 2009 were identiﬁed. Their clinical records were
eviewed through October 2009.
Results: Twelve patients with ﬂuoroquinolone-resistant
DR-TB and 7 patients with XDR-TB (including one probable
ase) were enroled. They were given levoﬂoxacin 600-
00mg daily together with linezolid and other second-line
gents. Linezolid was administered in 600mg twice-daily
osing in 14 patients for a median of 56 days [interquar-
ile range (IQR) 42-56 days], and 800mg once-daily dosing
n 5 patients for a median of 84 days (IQR 42-112 days). Of
hese 19 patients, 8 (42%) achieved sputum culture conver-
ion before receiving linezolid and other second-line agents
nd culture negativity persisted; 7 (37%) had culture con-
erted to negative after a median of 12 weeks (IQR 8-12
eeks) of treatment; 3 (16%) had transient bacteriological
onversion to negativity followed by reversion to positivity
fter withdrawal of linezolid; and 1 (5%) failed to achieve
ny sputum culture conversion.
Among the 14 patients who received 600mg twice-daily
osing, 4 (29%) had signiﬁcant gastrointestinal distur-
ance and 9 (64%) patients developed anemia (hemoglobin)
0 g/dL). Two (14%) tolerated treatment well without any
ide-effect. Among the 5 patients who received 800mg
nce-daily dosing, 2 (40%) had no adverse events, 2 (40%)
atients had anemia, and 2 (40%) experienced mild limb
aresthesia.
A total of 6 (32%) patients completed treatment with
elapse in one. Four (21%) defaulted from treatment. Two
11%) patients died, one from lung carcinoma and the other
rom TB. Seven (37%) patients were continuing treatment
ith one still on linezolid.
Conclusion: Complicated MDR-TB or XDR-TB may require
rolonged linezolid therapy. Linezolid administered as
00mg once daily appeared to be better tolerated than
